An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy
Open Access
- 25 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Evolution, Medicine, and Public Health
- Vol. 10 (1) , 439-446
Abstract
Background and objectives: Previously, we showed proof-of-concept in a mouse model that oral administration of cholestyramine prevented enrichment of daptomycin-resistant Enterococcus faecium in the gastrointestinal (GI) tract during daptomycin therapy. Cholestyramine binds daptomycin in the gut, which removes daptomycin selection pressure and so prevents the enrichment of resistant clones. Here, we investigated two open questions related to this approach: (i) can cholestyramine prevent the enrichment of diverse daptomycin mutations emerging de novo in the gut? and (ii) how does the timing of cholestyramine administration impact its ability to suppress resistance? Methodology: Mice with GI E. faecium were treated with daptomycin with or without cholestyramine, and E. faecium was cultured from feces to measure changes in daptomycin susceptibility. A subset of clones was sequenced to investigate the genomic basis of daptomycin resistance. Results: Cholestyramine prevented the enrichment of diverse resistance mutations that emerged de novo in daptomycin-treated mice. Whole-genome sequencing revealed that resistance emerged through multiple genetic pathways, with most candidate resistance mutations observed in the clsA gene. In addition, we observed that cholestyramine was most effective when administration started prior to the first dose of daptomycin. However, beginning cholestyramine after the first daptomycin dose reduced the frequency of resistant E. faecium compared to not using cholestyramine at all. Conclusions and implications: Cholestyramine prevented the enrichment of diverse daptomycin-resistance mutations in intestinal E. faecium populations during daptomycin treatment, and it is a promising tool for managing the transmission of daptomycin-resistant E. faecium.Keywords
Funding Information
- National Institutes of Health (R01 AI143852)
This publication has 26 references indexed in Scilit:
- Correlation between Mutations in liaFSR of Enterococcus faecium and MIC of Daptomycin: Revisiting Daptomycin BreakpointsAntimicrobial Agents and Chemotherapy, 2012
- The Problem of Auto-Correlation in ParasitologyPLOS Pathogens, 2012
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEffFly, 2012
- The rise of the Enterococcus: beyond vancomycin resistanceNature Reviews Microbiology, 2012
- Genetic Basis for In Vivo Daptomycin Resistance in EnterococciNew England Journal of Medicine, 2011
- Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humansJournal of Clinical Investigation, 2010
- Tablet—next generation sequence assembly visualizationBioinformatics, 2009
- P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of AmpicillinAntimicrobial Agents and Chemotherapy, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Safety Considerations with Gastrointestinally Active Lipid-Lowering DrugsThe American Journal of Cardiology, 2007